Dutch reimbursement authority suggests Roche's off-label Avastin for wet AMD instead of Novartis' Lucentis
This article was originally published in Scrip
The Dutch government is currently mulling whether or not to follow a recommendation from the CVZ, which gives advice on which treatments health insurers should fund, to "conditionally delist" Novartis' Lucentis (ranibizumab) as a second-line treatment for wet AMD, behind off-label Avastin (Roche's bevacizumab).
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.